{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T17:42:08Z","timestamp":1776793328050,"version":"3.51.2"},"reference-count":16,"publisher":"Informa UK Limited","issue":"5","funder":[{"DOI":"10.13039\/100014481","name":"Kite Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014481","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Leukemia &amp; Lymphoma"],"published-print":{"date-parts":[[2026,4,16]]},"DOI":"10.1080\/10428194.2025.2604306","type":"journal-article","created":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T13:09:24Z","timestamp":1767100164000},"page":"1184-1188","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Axicabtagene ciloleucel demonstrates superior outcomes over historically available treatments in relapsed\/refractory follicular lymphoma: 5-year comparative analysis between ZUMA-5 and SCHOLAR-5"],"prefix":"10.1080","volume":"67","author":[{"given":"John G.","family":"Gribben","sequence":"first","affiliation":[{"name":"Hematology and Oncology, Barts Cancer Institute","place":["London, UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Lia","family":"Palomba","sequence":"additional","affiliation":[{"name":"David H. Koch Center for Cancer Care, Memorial Sloan Kettering Cancer Center","place":["New York, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eve","family":"Limbrick-Oldfield","sequence":"additional","affiliation":[{"name":"RainCity Analytics","place":["Vancouver, Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madhu","family":"Palivela","sequence":"additional","affiliation":[{"name":"Kite, A Gilead Company","place":["Santa Monica, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steve","family":"Kanters","sequence":"additional","affiliation":[{"name":"RainCity Analytics","place":["Vancouver, Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alana M.","family":"Stilla","sequence":"additional","affiliation":[{"name":"RainCity Analytics","place":["Vancouver, Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caron A.","family":"Jacobson","sequence":"additional","affiliation":[{"name":"Hematologic Oncology, Dana-Farber Cancer Institute","place":["Boston, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sattva S.","family":"Neelapu","sequence":"additional","affiliation":[{"name":"Department of Lymphoma - Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center","place":["Houston, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olga","family":"Nikolajeva","sequence":"additional","affiliation":[{"name":"Kite, A Gilead Company","place":["Santa Monica, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiali H.","family":"Yan","sequence":"additional","affiliation":[{"name":"Kite, A Gilead Company","place":["Santa Monica, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markqayne D.","family":"Ray","sequence":"additional","affiliation":[{"name":"Kite, A Gilead Company","place":["Santa Monica, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Ghione","sequence":"additional","affiliation":[{"name":"David H. Koch Center for Cancer Care, Memorial Sloan Kettering Cancer Center","place":["New York, USA"]},{"name":"Roswell Park Comprehensive Cancer Center","place":["Buffalo, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2025,12,30]]},"reference":[{"key":"e_1_3_2_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-136834"},{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00591-X"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2021.278717"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/hs9.0000000000000745"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2022.281421"},{"key":"e_1_3_2_7_1","unstructured":"Administration FaD. FDA grants accelerated approval to axicabtagene ciloleucel for relapsed or refractory follicular lymphoma; 2023. Accessed February 21 2023. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-axicabtagene-ciloleucel-relapsed-or-refractory-follicular-lymphoma."},{"key":"e_1_3_2_8_1","unstructured":"Agency EM. EMA Recommends Extension of Therapeutic Indications for Axicabtagene Ciloleucel; 2023. Accessed February 21 2023. https:\/\/www.esmo.org\/oncology-news\/ema-recommends-extension-of-indications-for-axicabtagene-ciloleucel#:\u223c:text=On%2015%20September%202022%2C%20the product%20axicabtagene%20ciloleucel%20. (Yescarta)."},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-00668"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014375"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2024.01.011"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-186842"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2023.2171994"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1314583"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwj149"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-170469"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS7579"}],"container-title":["Leukemia &amp; Lymphoma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/10428194.2025.2604306","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T16:52:46Z","timestamp":1776790366000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/10428194.2025.2604306"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,30]]},"references-count":16,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,4,16]]}},"alternative-id":["10.1080\/10428194.2025.2604306"],"URL":"https:\/\/doi.org\/10.1080\/10428194.2025.2604306","relation":{},"ISSN":["1042-8194","1029-2403"],"issn-type":[{"value":"1042-8194","type":"print"},{"value":"1029-2403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,30]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ilal20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ilal20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-08-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-24","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}